Related Experiment Videos
[Congenital erythropoietic porphyria]
K Tanigawa1, N Takamura, S Yamashita
1Department of Preventive Medicine, Nagasaki University School of Medicine.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|June 1, 1995
Summary
Congenital erythropoietic porphyria (CEP), a rare genetic disorder, results from reduced uroporphyrinogen III synthase activity. This summary covers CEP epidemiology, symptoms, diagnostics, and treatment options.
Area of Science:
- Biochemistry
- Genetics
- Hematology
Context:
- Congenital erythropoietic porphyria (CEP), also known as Günther's disease, is an extremely rare autosomal recessive disorder.
- CEP is characterized by severe photosensitivity and abnormal heme synthesis.
- The disease arises from reduced activity of uroporphyrinogen III synthase (UROIIIS), a key enzyme in the heme biosynthetic pathway.
Purpose:
- To provide a comprehensive overview of congenital erythropoietic porphyria (CEP).
- To detail the epidemiology, clinical signs and symptoms, laboratory findings, and therapeutic strategies for CEP.
- To highlight recent advancements in understanding the molecular genetic basis of CEP.
Summary:
- CEP is caused by mutations in the UROIIIS gene, leading to enzyme deficiency.
- Clinical manifestations include mutilating cutaneous photosensitivity and hematological abnormalities.
- Diagnosis involves assessing UROIIIS activity and identifying specific gene mutations.
Impact:
- Enhances understanding of CEP's genetic underpinnings and clinical presentation.
- Provides valuable information for clinicians managing rare genetic disorders.
- Contributes to the knowledge base for developing targeted therapies for porphyrias.